publication date: Nov. 14, 2014

2015 Breakthrough Prize Winners Announced at Gala

 

The Breakthrough Prize Foundation announced the recipients of its prizes in life sciences and fundamental physics, who will receive awards of $3 million.

The recipients of the 2015 Breakthrough Prizes in Life Sciences are:

Alim Louis Benabid, of Joseph Fourier University, for the development of high-frequency deep brain stimulation, which has revolutionized the treatment of Parkinson’s disease.

C. David Allis, of The Rockefeller University, for the discovery of covalent modifications of histone proteins and their roles in the regulation of gene expression and chromatin organization.

Victor Ambros, of University of Massachusetts Medical School, and Gary Ruvkun, of Massachusetts General Hospital and Harvard Medical School, for the discovery of genetic regulation by microRNAs. Each received a $3 million award.

Jennifer Doudna, of University of California, Berkeley, Howard Hughes Medical Institute and Lawrence Berkeley National Laboratory, and Emmanuelle Charpentier, of Helmholtz Center for Infection Research and Umeå University, for harnessing a mechanism of bacterial immunity into a general technology for editing genomes. Each received a $3 million award.

The Breakthrough Prize in Fundamental Physics recognized a collaboration of 51 total prize recipients that discovered that the expansion of the universe is accelerating, rather than slowing. The team included Saul Perlmutter, of the University of California, Berkeley and the Lawrence Berkeley National Laboratory; Brian Schmidt, of Australian National University; and Adam Riess, of Johns Hopkins University and the Space Telescope Science Institute; and members … Continue reading 40-43 2015 Breakthrough Prize Winners Announced at Gala

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.